Your browser doesn't support javascript.
Designing of Potential Polyvalent Vaccine Model for Respiratory Syncytial Virus by System Level Immunoinformatics Approaches.
Naqvi, Syeda Tahira Qousain; Yasmeen, Mamoona; Ismail, Mehreen; Muhammad, Syed Aun; Nawazish-I-Husain, Syed; Ali, Amjad; Munir, Fahad; Zhang, QiYu.
  • Naqvi STQ; Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University Multan, Pakistan.
  • Yasmeen M; Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University Multan, Pakistan.
  • Ismail M; Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University Multan, Pakistan.
  • Muhammad SA; Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University Multan, Pakistan.
  • Nawazish-I-Husain S; University College of Pharmacy, Punjab University Lahore, Pakistan.
  • Ali A; ASAB, National University of Sciences and Technology (NUST), Islamabad, Pakistan.
  • Munir F; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, China.
  • Zhang Q; Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Biomed Res Int ; 2021: 9940010, 2021.
Article in English | MEDLINE | ID: covidwho-1259034
ABSTRACT

BACKGROUND:

Respiratory syncytial virus (RSV) infection is a public health epidemic, leading to around 3 million hospitalization and about 66,000 deaths each year. It is a life-threatening condition exclusive to children with no effective treatment.

METHODS:

In this study, we used system-level and vaccinomics approaches to design a polyvalent vaccine for RSV, which could stimulate the immune components of the host to manage this infection. Our framework involves data accession, antigenicity and subcellular localization analysis, T cell epitope prediction, proteasomal and conservancy evaluation, host-pathogen-protein interactions, pathway studies, and in silico binding affinity analysis.

RESULTS:

We found glycoprotein (G), fusion protein (F), and small hydrophobic protein (SH) of RSV as potential vaccine candidates. Of these proteins (G, F, and SH), we found 9 epitopes for multiple alleles of MHC classes I and II bear significant binding affinity. These potential epitopes were linked to form a polyvalent construct using AAY, GPGPG linkers, and cholera toxin B adjuvant at N-terminal with a 23.9 kDa molecular weight of 224 amino acid residues. The final construct was a stable, immunogenic, and nonallergenic protein containing cleavage sites, TAP transport efficiency, posttranslation shifts, and CTL epitopes. The molecular docking indicated the optimum binding affinity of RSV polyvalent construct with MHC molecules (-12.49 and -10.48 kcal/mol for MHC classes I and II, respectively). This interaction showed that a polyvalent construct could manage and control this disease.

CONCLUSION:

Our vaccinomics and system-level investigation could be appropriate to trigger the host immune system to prevent RSV infection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Combined / Respiratory Syncytial Virus, Human / Respiratory Syncytial Virus Infections / Computational Biology Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Biomed Res Int Year: 2021 Document Type: Article Affiliation country: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Combined / Respiratory Syncytial Virus, Human / Respiratory Syncytial Virus Infections / Computational Biology Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Biomed Res Int Year: 2021 Document Type: Article Affiliation country: 2021